scholarly journals Use of Sickness Benefits by Patients With Metastatic Breast Cancer – A Swedish Cohort Study

Author(s):  
Renske Altena ◽  
Sofie A.M. Gernaat ◽  
Ulla Wilking ◽  
Narsis A. Kiani ◽  
Aina Johnsson ◽  
...  

Abstract Background Advances in the treatment of metastatic breast cancer (mBC) have led to improved life expectancy. Many cancer survivors desire to return to paid work to enhance their sense of well-being. For patients with mBC, little is known about how the diagnosis impacts ability to work or the factors that increase the need for sickness benefits. Patients and methods Data were collected from two Swedish national registers, for females ages 18 to 63 years in the Stockholm-Gotland healthcare region with a new diagnosis of mBC from 1997 through 2011. Type of first-line palliative treatment was identified in medical records of a subset of the study population. Use of sickness absence (SA) and disability pension (DP) by these patients during the year before and one and two years after mBC diagnosis was determined from a third register. Regression analysis was performed to ascertain which covariate factors were associated with long-term (> 30 days) SA. Results A total of 1,240 patients were evaluated the year before and the first year after mBC diagnosis; only 805 patients were still alive and evaluated the second year after diagnosis. The proportions of patients having SA and DP were 56.0% and 24.8% the year before, 69.9% and 28.9% the first year after, and 64.0% and 34.7% the second year after diagnosis, respectively. Adjusted odds of having long-term SA were significantly higher at 1 and 2 years after diagnosis for patients with age < 45 years (AOR = 3.43 and AOR = 1.70, respectively), early calendar year of diagnosis (AOR = 1.72 and AOR = 1.79, respectively), metachronous mBC (AOR = 4.85 and AOR = 4.52, respectively), and SA ≥ 90 days the year before diagnosis (AOR = 3.44 and AOR = 1.98, respectively). Odds were also significantly higher the second after diagnosis for patients treated with chemotherapy (AOR = 1.81) or radiotherapy (AOR = 2.23), compared to those treated with hormonal therapy, Conclusions Rates of SA and DP increase after a diagnosis of mBC. Women who are younger, develop metachronous mBC, use SA heavily before mBC, and receive chemotherapy or radiotherapy have a greater need for sickness benefits after an mBC diagnosis.

2017 ◽  
Vol 44 ◽  
pp. 16-21 ◽  
Author(s):  
Michael H. Antoni ◽  
Jamie M. Jacobs ◽  
Laura C. Bouchard ◽  
Suzanne C. Lechner ◽  
Devika R. Jutagir ◽  
...  

2017 ◽  
Vol 5 (1) ◽  
pp. 1-7
Author(s):  
Young Hoon Noh ◽  
Yun Gyoung Kim ◽  
Ji Hyun Kim ◽  
Hyang Suk Choi ◽  
Seok Joon Lee ◽  
...  

1996 ◽  
Vol 14 (8) ◽  
pp. 2197-2205 ◽  
Author(s):  
P A Greenberg ◽  
G N Hortobagyi ◽  
T L Smith ◽  
L D Ziegler ◽  
D K Frye ◽  
...  

PURPOSE To determine the long-term clinical course of patients with metastatic breast cancer (MBC) who achieved a complete remission with doxorubicin-alkylating agent-containing combination chemotherapy programs. PATIENTS AND METHODS To assess the long-term prognosis of MBC, we reviewed our experience with 1,581 patients treated on consecutive doxorubicin and alkylating agent-containing front-line treatment protocols between 1973 and 1982. Treatment was administered for a maximum duration of 2 years. Characteristics of long-term survivors were evaluated, and hazard rates for progression were calculated. RESULTS From this group, 263 (16.6%) achieved complete responses (CR) and 49 (3.1%) remained in CR for more than 5 years. After a median duration of 191 months, 26 patients remain in first CR, four patients died in CR at times ranging from 118 to 234 months, 18 patients died of breast cancer, and one is alive with metastatic disease. Compared with the overall CR and total patient populations, the long-term CR group had more premenopausal patients, a younger median age, a lower tumor burden, and better performance status. The hazard function shows a substantial drop in risk of progression after approximately 3 years from initiation of therapy. Ten long-term CR patients developed second primary cancers: breast (3), ovary (2), pancreas (1), endometrium (1), colon (1), head and neck (1), and lung (1). CONCLUSION Most patients with MBC treated with systemic therapies have only temporary responses to treatment, but some patients continue in CR following initial treatment. These data show that a small percentage of patients achieve long-term remissions with standard chemotherapy regimens. Remission consolidation strategies are needed.


2014 ◽  
Vol 25 ◽  
pp. iv128
Author(s):  
A. Storozhakova ◽  
L. Vladimirova ◽  
Y. Prgedetsky ◽  
I. Popova ◽  
N.A. Abramova ◽  
...  

2019 ◽  
Vol 19 (4) ◽  
pp. e522-e533 ◽  
Author(s):  
Leena Tiainen ◽  
Mari Hämäläinen ◽  
Tiina Luukkaala ◽  
Minna Tanner ◽  
Outi Lahdenperä ◽  
...  

2020 ◽  
Vol 123 (8) ◽  
pp. 1219-1222
Author(s):  
Naomi Walsh ◽  
Charlotte Andrieu ◽  
Peter O’Donovan ◽  
Cecily Quinn ◽  
Alanna Maguire ◽  
...  

Author(s):  
Pooja Murthy ◽  
Kelley M Kidwell ◽  
Dafydd G Thomas ◽  
Jennifer J Griggs ◽  
Sofia D Merajver ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document